ESSA Pharma Inc. (EPIX) Announces Change to its Board of Directors

March 26, 2021 4:06 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Ari Brettman, M.D., has stepped down from ESSA's Board of Directors, which he has been a member of since 2019. Dr. Brettman is a Managing Director of Blackstone's Life Science Group and will be assuming more responsibilities in this role.

"We are extremely grateful to Dr. Brettman for his strong leadership and valuable insights as a member of the Board of Directors," said Richard M. Glickman, Chairman of ESSA's Board of Directors. "On behalf of the entire Board and Executive Management Team, I would like to thank Dr. Brettman for his contributions and continued support, and we wish him success in his future endeavors."

"It has been an honor to serve on ESSA's Board and witness the Company's tremendous growth over the past few years," said Dr. Brettman. "ESSA's passionate and experienced management team positions the Company for continued success and I look forward to following ESSA's progress and the clinical development of the lead product candidate, EPI-7386, which has the potential to transform the treatment paradigm for prostate cancer."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Board Changes, Corporate News

Related Entities

Twitter